Multiple myeloma.
Kyle
Robert A
RA
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA. kyle.robert@mayo.edu
Rajkumar
S Vincent
SV
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001897:Boronic Acids / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000069286:Bortezomib; D003131:Combined Modality Therapy; D018450:Disease Progression; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D010265:Paraproteinemias / Q000235:genetics / Q000503:physiopathology; D011480:Protease Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D011719:Pyrazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D012074:Remission Induction; D033581:Stem Cell Transplantation; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide